MD3423496T2 - Anticorpi neantagoniști direcționați împotriva lanțurilor alfa ale domeniului extracelular al receptorului IL7 și utilizarea acestora în tratamentul cancerului - Google Patents
Anticorpi neantagoniști direcționați împotriva lanțurilor alfa ale domeniului extracelular al receptorului IL7 și utilizarea acestora în tratamentul canceruluiInfo
- Publication number
- MD3423496T2 MD3423496T2 MDE20190066T MDE20190066T MD3423496T2 MD 3423496 T2 MD3423496 T2 MD 3423496T2 MD E20190066 T MDE20190066 T MD E20190066T MD E20190066 T MDE20190066 T MD E20190066T MD 3423496 T2 MD3423496 T2 MD 3423496T2
- Authority
- MD
- Moldova
- Prior art keywords
- receptor
- extracellular domain
- antibodies directed
- directed against
- alpha chain
- Prior art date
Links
- 108010038498 Interleukin-7 Receptors Proteins 0.000 title abstract 6
- 102000010782 Interleukin-7 Receptors Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 abstract 2
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 abstract 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000052622 human IL7 Human genes 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Invenţia se referă la anticorpi umanizaţi direcţionaţi împotriva domeniului extracelular al lanţului alfa al receptorului pentru interleukina 7 (IL-7), în special receptorul pentry IL-7 uman exprimat în celule umane (numit de asemenea IL-7Ralpha sau IL-7Ra sau CD127) şi care nu interferează cu căile semnalelor IL-7 sau TSLP.Anticorpul conform invenţiei nu are efect antagonic asupra receptoulului IL-7, dar poate încă prezenta activitate citotoxică împotriva celulelor CD127 pozitive. Într-un exemplu de realizare particular, anticorpul nu are efect agonist asupra receptorului IL-7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301271P | 2016-02-29 | 2016-02-29 | |
| PCT/IB2017/000293 WO2017149394A1 (en) | 2016-02-29 | 2017-02-28 | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3423496T2 true MD3423496T2 (ro) | 2020-01-31 |
Family
ID=58530580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20190066T MD3423496T2 (ro) | 2016-02-29 | 2017-02-28 | Anticorpi neantagoniști direcționați împotriva lanțurilor alfa ale domeniului extracelular al receptorului IL7 și utilizarea acestora în tratamentul cancerului |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11230602B2 (ro) |
| EP (1) | EP3423496B1 (ro) |
| JP (1) | JP7053479B2 (ro) |
| KR (1) | KR20180118746A (ro) |
| CN (1) | CN109195987B (ro) |
| AU (1) | AU2017225495B2 (ro) |
| BR (1) | BR112018067479A2 (ro) |
| CA (1) | CA3014313A1 (ro) |
| CY (1) | CY1122072T1 (ro) |
| DK (1) | DK3423496T3 (ro) |
| ES (1) | ES2737307T3 (ro) |
| HR (1) | HRP20191445T1 (ro) |
| HU (1) | HUE045183T2 (ro) |
| IL (1) | IL261330B2 (ro) |
| LT (1) | LT3423496T (ro) |
| MA (1) | MA43767B1 (ro) |
| MD (1) | MD3423496T2 (ro) |
| ME (1) | ME03446B (ro) |
| PL (1) | PL3423496T3 (ro) |
| PT (1) | PT3423496T (ro) |
| RS (1) | RS59223B1 (ro) |
| SI (1) | SI3423496T1 (ro) |
| WO (1) | WO2017149394A1 (ro) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| US20200362300A1 (en) * | 2017-08-29 | 2020-11-19 | Ose Immunotherapeutics | Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy |
| JP2022539753A (ja) * | 2019-06-28 | 2022-09-13 | ザ ユニバーシテイ オブ メルボルン | ガンマデルタｔ細胞を阻害する、または活性化させる方法 |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| WO2021222227A1 (en) * | 2020-04-27 | 2021-11-04 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting cd127 and use thereof |
| JP2023526523A (ja) * | 2020-05-18 | 2023-06-21 | ジュマー－ヴァイナハト，ハッサン | フィラデルフィア染色体陽性急性リンパ芽球性白血病の治療のための組成物 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CA2655392A1 (en) | 2006-05-31 | 2007-12-06 | The Regents Of The University Of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| US8940303B2 (en) | 2010-01-28 | 2015-01-27 | Glaxo Group Limited | CD127 binding proteins |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| US20150297310A1 (en) | 2014-04-17 | 2015-10-22 | Georgia Regents Research Institute, Inc. | Methods for selecting a treatment for cancer |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
-
2017
- 2017-02-28 DK DK17716593.3T patent/DK3423496T3/da active
- 2017-02-28 LT LTEP17716593.3T patent/LT3423496T/lt unknown
- 2017-02-28 CN CN201780014099.2A patent/CN109195987B/zh active Active
- 2017-02-28 MD MDE20190066T patent/MD3423496T2/ro not_active IP Right Cessation
- 2017-02-28 AU AU2017225495A patent/AU2017225495B2/en active Active
- 2017-02-28 PT PT17716593T patent/PT3423496T/pt unknown
- 2017-02-28 BR BR112018067479A patent/BR112018067479A2/pt unknown
- 2017-02-28 EP EP17716593.3A patent/EP3423496B1/en active Active
- 2017-02-28 ME MEP-2019-215A patent/ME03446B/me unknown
- 2017-02-28 CA CA3014313A patent/CA3014313A1/en active Pending
- 2017-02-28 ES ES17716593T patent/ES2737307T3/es active Active
- 2017-02-28 WO PCT/IB2017/000293 patent/WO2017149394A1/en active Application Filing
- 2017-02-28 IL IL261330A patent/IL261330B2/en unknown
- 2017-02-28 JP JP2018545380A patent/JP7053479B2/ja active Active
- 2017-02-28 RS RSP20190987 patent/RS59223B1/sr unknown
- 2017-02-28 MA MA43767A patent/MA43767B1/fr unknown
- 2017-02-28 SI SI201730078T patent/SI3423496T1/sl unknown
- 2017-02-28 HU HUE17716593A patent/HUE045183T2/hu unknown
- 2017-02-28 PL PL17716593T patent/PL3423496T3/pl unknown
- 2017-02-28 US US16/080,572 patent/US11230602B2/en active Active
- 2017-02-28 KR KR1020187028377A patent/KR20180118746A/ko not_active Application Discontinuation
-
2019
- 2019-08-09 HR HRP20191445 patent/HRP20191445T1/hr unknown
- 2019-08-23 CY CY20191100905T patent/CY1122072T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200308288A1 (en) | 2020-10-01 |
| DK3423496T3 (da) | 2019-08-19 |
| SI3423496T1 (sl) | 2019-10-30 |
| ES2737307T3 (es) | 2020-01-13 |
| IL261330B2 (en) | 2023-03-01 |
| CA3014313A1 (en) | 2017-09-08 |
| US11230602B2 (en) | 2022-01-25 |
| IL261330B (en) | 2022-11-01 |
| CN109195987B (zh) | 2022-05-27 |
| IL261330A (en) | 2018-10-31 |
| RS59223B1 (sr) | 2019-10-31 |
| JP2019515648A (ja) | 2019-06-13 |
| MA43767A (fr) | 2019-01-09 |
| AU2017225495B2 (en) | 2024-05-09 |
| WO2017149394A1 (en) | 2017-09-08 |
| EP3423496B1 (en) | 2019-07-03 |
| PT3423496T (pt) | 2019-09-05 |
| AU2017225495A1 (en) | 2018-08-23 |
| PL3423496T3 (pl) | 2020-01-31 |
| HRP20191445T1 (hr) | 2019-11-15 |
| JP7053479B2 (ja) | 2022-04-12 |
| MA43767B1 (fr) | 2019-08-30 |
| CY1122072T1 (el) | 2020-11-25 |
| HUE045183T2 (hu) | 2019-12-30 |
| LT3423496T (lt) | 2019-09-25 |
| KR20180118746A (ko) | 2018-10-31 |
| ME03446B (me) | 2020-01-20 |
| BR112018067479A2 (pt) | 2019-01-15 |
| CN109195987A (zh) | 2019-01-11 |
| EP3423496A1 (en) | 2019-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3423496T2 (ro) | Anticorpi neantagoniști direcționați împotriva lanțurilor alfa ale domeniului extracelular al receptorului IL7 și utilizarea acestora în tratamentul cancerului | |
| MD3551664T2 (ro) | Anticorpi și polipeptide direcționate împotriva CD 127 | |
| CO2020000438A2 (es) | Anticuerpos anti-ctla-4 y sus usos | |
| CO2019012353A2 (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1 | |
| MD3601358T2 (ro) | Anticorpi anti-TREM2 și metode de utilizare a acestora | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| CO2020013392A2 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
| MD3328889T2 (ro) | Constructe de anticorp bispecific de legare a DLL3 şi CD3 | |
| NZ741067A (en) | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use | |
| PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
| EA202090204A1 (ru) | Анти-cd137 антитела | |
| MD3355919T2 (ro) | Terapie combinată cu utilizarea inhibitorilor factorului de creștere și diferențiere uman 15 (GDF-15) și a blocanților punctelor de control imunitar | |
| PH12018501525A1 (en) | Tgfbeta 2 antibodies | |
| MX2021001268A (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| PH12020550930A1 (en) | Human igg fc domain variants with improved effector function | |
| MA52889A (fr) | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires | |
| EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
| PH12020552235A1 (en) | Anti-cd40 antibodies for use in treating autoimmune disease | |
| MA51326A (fr) | Dispositif d'éclairage de la chair | |
| EA202190411A1 (ru) | Химерные антигенные рецепторы к нескольким изоформам hla-g | |
| EA201990824A1 (ru) | Антитела, которые связываются с интерлейкином-2, и их применение | |
| PL416359A1 (pl) | Przeciwciała monoklonalne rozpoznające swoiście psi antygen DLA-DR i ich zastosowania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |